Nonalcoholic steatohepatitis

Seminars in Liver Disease

Volumn 19, Issue 2, 1999, Pages 221-230

  Diehl, Anna Mae ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alcohol like hepatitis; Fatty liver; Steatonecrosis

Indexed keywords

CYTOKINE; ENDOTOXIN; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL FEATURE; DISEASE CLASSIFICATION; FAT NECROSIS; FATTY LIVER; HEPATITIS; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SEROLOGY;

EID: 0032771475     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007111     Document Type: Review

References (73)

1. Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med 1979;67:811-816
2. Batman PA, Scheuer PJ. Diabetic hepatitis preceding the onset of glucose intolerance. Histopathology 1985;9:237-243
3. Diehl AM, Goodman Z, Ishak KG. Alcohol-like liver disease in nonalcoholics. A clinical and histopathological comparison with alcohol-induced liver injury. Gastroenterology 1989;95:1056-1060
4. Lee RG. Nonalcoholic steatohepatitis. A study of 49 patients. Hum Pathol 1989;20:594-599
5. Ludwig J, Viggiano RT, McGill DB. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:342-348
6. Torosis JD, Barwick KW, Miller JD, et al. Nonalcoholic Laennec's: Clinical characteristics and long term follow up. Hepatology 1985;237-241
7. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: An autospy study with analysis of risk factors. Hepatology 1990;12:1106-1110
8. Powell EE, Cooksley GE, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: A follow-up study of 42 patients follow for up to 21 years. Hepatology 1990;11:74-80
9. Powell EE, Searle J, Mortimer R. Steatohepatitis associated with limb lipodystrophy. Gastroenterology 1989;97:1022-1024
10. Fouin-Fortenet H, LeQuernec L, Erlinger S, et al. Hepatic alterations during total parenteral nutrition in patients with inflammatory bowel disease: A possible consequence of lithocholate toxicity. Gastroenterology 1982;82:932-938
11. Itoh S, Igarashi M, Tsukada T, et al. Nonalcoholic fatty liver with alcoholic hyalin after long-term glucocorticoid therapy. Acta Hepatogastroenterol 1977;24:415-419
12. Kroyer JM, Talbert VMJ. Morphologic liver changes in intestinal bypass patients. Am J Surg 1980;139:855-860
13. Lewis JH, Ranard RC, Caruso A, et al. Amiodarone hepatotoxicity: Prevalence and clinicopathologic correlations among 104 patients. Hepatology 1989;9:679-683
14. Passaye D, Bichara M, Feldman G, et al. Perhexilene maleate-induced cirrhosis. Gastroenterology 1979;76:170-175
15. Poucell S, Ireton J, Valencia-Mayoral P, et al. Amiodarone-associated phospholipidosis and fibrosis of the liver. Light, immunohistochemical, and electron microscopic studies. Gastroenterology 1984;86:926-936
16. Seki K, Minami T, Nishikawa M, et al. Nonalcoholic steatohepatitis induced by massive doses of synthetic estrogens. Gastroenterol Jpn 1984;18:232-237
17. Bacon B, Faravash MJ, Janney CG, et al. Nonalcoholic steatohepatitis: An expanded clinical entity. Gastroenterology 1994; 107:1103-1106
18. Braillon A, Capron JP, Herve MA, et al. Liver in obesity. Gut 1985;26:133-139
19. Halverson JD, Wise L, Wazna MF, et al. Jejunoileal bypass for morbid obesity: A critical appraisal. Am J Med 1978;64:461-467
20. Leevy CM. Fatty liver: A study of 270 patients with biopsy proven fatty liver and a review of the literature. Medicine (Baltimore) 1962;4:249-258
21. Teli M, Oliver FW, Burt AD, et al. A natural history of nonalcoholic fatty liver: A follow-up study. Hepatology 1995;22:1714-1717
22. Van Thiel DH. Diabetes mellitus and hepatobiliary disease. Curr Concept Gastroenterol 1985;20:3-20
23. Sheth SG, Gordon FD, Chopar S. Nonalcoholic steatohepatitis. Ann Intern Med 1997;126:137-145
24. Fortang IS, Belitsos PC, Chaisson RE. et al. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. Am J Gastroenterol 1995;90:1433-1438
25. Zimmerman HJ, Maddrey WC. Toxic and drug-induced hepatitis. In: Schiff L, Schiff ER, eds. Diseases of the Liver, vol 6. Philadelphia: JB Lippincott, 1987:591-607
26. Boudreaux JP, Hayes DH, Mizrahi S, et al. Fulminant hepatic failure, hepatorenal syndrome, and necrotizing pancreatitis after minocycline hepatotoxicity. Transplant Proc 1993;25:1873-1876
27. Zebrini C, Weinberg DS, Hollister KA, et al. DNA ploidy abnormalities in the liver of children with hereditary tyrosinemia type 1. Correlation with histopathologic features. Am J Pathol 1992;140:1111-1115
28. Cohen JA, Kaplan MM. The SGOT/SGPT ratio: An indicator of alcoholic liver disease. Dig Dis Sci 1979;24:835-839
29. George DK, Goldwurm S, MacDonald GA, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998;114:311-318
30. Lelbach WK. Epidemiology of alcoholic liver disease. Prog Liver Dis 1976;5:494-513
31. Pequignot G, Tuyns AS, Berta JL. Ascitic cirrhosis in relationship to alcohol consumption, Int J Epidemiol 1978,7:113-120
32. Sanson-Fisher R. The measurement of alcohol consumption and alcohol related problems. Aust Drug Alcohol Rev 1986;5:309-313
33. Mulford HA, Miller DE. Drinking in Iowa V. Drinking and alcoholic drinking. QJ Stud Alcohol 1960;21:483-491
34. Lumeng L. New diagnostic markers of alcohol abuse. Hepatology 1986;6:42-47
35. Fletcher LM, Kwoh-Gain L, Powell E, et al. Markers of chronic alcohol ingestion in nonalcoholic steatohepatitis: An aid to diagnosis. Hepatology 1991;13:455-459
36. Rogers DW, Lee CH, Pound DC, et al. Hepatitis C virus does not cause nonalcoholic steatohepatitis. Dig Dis Sci 1992;37:1644-1649
37. Rofsky NM, Fleshaker H. CT and MRI of diffuse liver disease. Semin Liv Dis 1995;16:16-23
38. Levenson H, Greensite F, Hoefs J, et al. Fatty infiltration of the liver: Quantification with phase-contrast MR imaging at 1.5 T vs. biopsy. AJR 1991;156:307-111
39. Lee RG. Nonalcholic steatohepatitis: Tightening the morphological screws on a hepatic rambler. Hepatology 1995;21:1742-1744
40. Falchuk KR, Fiske SC, Haggit RC, et al. Pericentral hepataic fibrosis and intracellular hyalin in diabetes mellitus. Gastroenterology 1980;78:535-540
41. Silverman JF, O'Brien KF, Long S, et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 1990;85:1345-1355
42. Lee RG. Nonalcoholic steatohepatitis: Tightening the morphological screws on a hepatic rambler. Hepatology 1995;21:1742-1744
43. Bird GLA, Williams R. Factors determining cirrhosis in alcoholic liver disease. Mol Aspects Med 1988;10:97-103
44. Galambos J. Natural history of alcoholic hepatitis. III. Histologic changes. Gastroenterology 1972;56:515-522
45. Pares A, Caballeria J, Brugera M. Histologic course of alcoholic hepatitis: Influence of abstinence, sex, and extent of hepatic damage. J Hepatol 1986;2:33-38
46. Alexander FF, Lischner W, Galambos J. Natural history of alcoholic hepatitis II. the long term prognosis. Gastroenterology 1971;56:515-521
47. Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med 1990;113:299-300
48. Randall B. Fatty liver and sudden death. A review. Hum Pathol 1980;11:167-173
49. Requarth JA, Burchard KW, Colacchio TA, et al. Long-term morbidity following jejunoileal bypass. The continuing potential need for surgical reversal. Arch Surg 1995;130:318-325
50. Haines NW, Baker AL, Boyer JL, et al. Prognostic indications of hepatic injury following jejunal ileal bypass for refractory obesity: A prospective study. Hepatology 1981;1:161-165
51. Vyberg M, Ravn V, Andersen B. Patterns of progression of liver injury following jejunoileal bypass for morbid obesity. Liver 1987;7:271-276
52. Shelden GF, Petersen SR, Sanders R. Hepatic dysfunction during hyperalimentation. Arch Surg 1978;113:504-508
53. Peden VH, Witzelben CI, Skelton MA. Total parenteral nutrition. J Pediatr 1971;78:180 (letter)
54. Nussbaum MS, Fisher JE. Pathogenesis of hepatic steatosis during total parenteral nutrition. Surg Annu 1991;2:1-18
55. Freund HR, Muggia-Sullam M, LaFrance R, et al. A possible beneficial effect of metronidazole in reducing TPN-associated liver function derangements. J Surg 1985;38:356-360
56. Nanji AA, Zhao S, Sadrzadeh SMH, et al. Markedly enhanced cytochrome P450 2E1 induction and lipid peroxidation is associated with severe liver injury in fish oil-ethanol fed rats. Alcohol Clin Exp Res 1994;18:1280-1285
57. Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996;111: 1645-1653
58. Weltman MD, Farrell GC, Hall P, et al. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998;27:128-133
59. McClain CJ, Hill DB, Schmidt J, Diehl AM. Cytokines and alcoholic liver disease. Semin Liver Dis 1993;13:170-182
60. Hammond MK, Lapointe GR, Feicht PH, et al. IL-8 induces neutrophil chemotaxis predominantly via type 1 IL-8 receptors. J Immunol 1995;155:1428-1434
61. Capron JP, Herve MA, Ginestron JL, et al. Metronidazole in prevention of cholestasis associated with total parenteral nutrition. Lancet 1983;1:446-449
62. Yang SQ, Lin HZ, Lane MD, et al. Obesity increases sensitivity to endotoxin liver injury: Implications for pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 1997;94:2557-2562
63. Loffreda S, Yang SQ, Lin HZ, et al. Leptin regulates proinflammatory immune responses. FASEB J 1998;12:57-65
64. Lee F-Y, Li Y, Yang EK, et al. Phenotypic abnormalities in macrophages from leptin-deficient, obese mice. Am J Physiol Cell Physiol 1999;276:C386-C394
65. Berkowitz D. Metabolic changes associated with obesity before and after weight reduction. JAMA 1964;187:103-110
66. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990;99: 1408-1411
67. Capron JP, Delamarre M, Dupas JL, et al. Fasting in obesity: Another cause of liver injury with alcoholic hyaline? Dig Dis Sci 1982;54:374-377
68. Abdelmalek M, Ludwig J, Lindor K. Two cases from the spectrum of nonalcoholic steatohepatitis. J Clin Gastroenterol 1995;20:127-131
69. Moxley RT, Posefsky T, Lockwood DH. Protein nutrition and liver disease after jejunoileal bypass for morbid obesity. N Engl J Med 1974;290:921-925
70. Heimburger SL, Seiger E, Logerfo P, et al. Reversal of severe fatty hepatic infiltration after jejunoileal bypass for morbid obesity by calorie-free amino acid infusion. Am J Surg 1975;129:70-78
71. Wolfe RR, O'Donnell TF, Stone MD. Investigation of factors determining the optimal glucose infusion rate in total parenteral nutrition. Metabolism 1980;29:892-897
72. DiLuzio N, Costales F. Inhibition of ethanol and carbon tetrachloride induced fatty liver by antioxidants. Exp Mol Pathol 1965;4:141-145
73. Garcia-Ruiz C, Morales A, Ballesta A, et al. Effect of chronic ethanol feeding on glutathione and functional intergrity of mitochondria in perioportal perivenous rat hepatocytes. J Clin Invest 1994;94:193-201